Cue Biopharma Announces Appointment of Anish Suri, Ph.D. as Chief Scientific Officer
Cue Biopharma, Inc. (CUE)
US:NASDAQ Investor Relations:
cuebiopharma.gcs-web.com/news-releases
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., April 25, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancer and autoimmune diseases, announced today that Anish Suri, Ph.D. has been appointed as Senior Vice President and Chief Scientific Officer. Dr. Suri, who most recently served as Senior Director of Janssen Immunosciences in Belgium, brings more than 20 years of experience to Cue Biopharma’s leadership team with a focus on immuno-oncology, autoimmune disorders, inflammation and translational medicine. “Having a senior scientific leader with Anish’s background and expertise enhances the core strengths of our leadership team and further enables our strategic mission of developing next-generation, precision immunotherapies, offering new hope to patients with serious or life-threatening conditions,” said Daniel Passeri, M.Sc., J
Show less
Read more
Impact Snapshot
Event Time:
CUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CUE alerts
High impacting Cue Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
CUE
News
- Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now [Yahoo! Finance]Yahoo! Finance
- Cue Biopharma, Inc. (NASDAQ: CUE) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $8.00 price target on the stock.MarketBeat
- Cue Biopharma, Inc. (NASDAQ: CUE) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock.MarketBeat
- Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights [Yahoo! Finance]Yahoo! Finance
- Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business HighlightsGlobeNewswire
CUE
Earnings
- 8/8/23 - Beat
CUE
Sec Filings
- 3/28/24 - Form 10-K
- 3/28/24 - Form S-8
- 3/11/24 - Form SC
- CUE's page on the SEC website